JPstock / Shutterstock.com
General Electric (GE) will sell its biopharma business, which generated $3 billion in revenues for the conglomerate last year, to Danaher in a $21.4 billion deal.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
General Electric, life sciences, biopharma, biopharmaceutical drugs, Danaher, agreement of sale